• Home
  • About Us
  • Science
    • Active Immunotherapies
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Latest News

Featured News

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

Jul 22, 2025

Select the category

  • All categories
  • Covid-19
  • GlyMab
  • Immunobody
  • Interviews
  • iSCIB1+
  • Latest News
  • Media Coverage
  • Modi-1
  • Modi-2
  • Moditope
  • News
  • Presentations
  • Regulatory News
  • SCIB1

Select the year

  • All years
  • 2022
  • 2023
  • 2024
  • 2025
Clear Filters
U

Issue of share options

May 21, 2024

Scancell announces multiple upcoming presentations at the 21st CIMT Annual Meeting

May 9, 2024

Scancell to present at the Annual Immuno-Oncology Summit Europe

April 17, 2024

Scancell to Present at 2024 AACR Annual Meeting

April 4, 2024

First Patient dosed with iSCIB1+ in SCOPE trial

March 27, 2024

Appointment of Sath Nirmalananthan to the Board of Directors

March 14, 2024
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 5
No results found.

Regulatory News Archive

View archive

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    About Us
    Leadership Team
    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy